NewZ NewZ with a Zeal
IGM Biosciences Inc (NASDAQ: IGMS) shares tumbled 40% Monday after the release of data from a phase 1 trial of a drug for patients with advanced B cell malignancies. Overall, out of the 38 patients evaluable for efficacy,
Related Articles
Check Also
Burnt Allies: Japan, S Korea Toe Cautious Line After Trump Tariffs
(MENAFN – Asia Times)Two months into US President Donald Trump’s second term, the liberal international …
What does the Barefoot Investor have to say about whether the ‘Trump Slump’ will last?
Here’s how one of Australia’s leading finance experts is thinking about the tariff.The post What …